PT - JOURNAL ARTICLE AU - Jill K. Morris AU - Colin S. McCoin AU - Kelly N. Fuller AU - Casey S. John AU - Heather M. Wilkins AU - Xiaowan Wang AU - Palash Sharma AU - Jeffrey M. Burns AU - Eric D. Vidoni AU - Jonathan D. Mahnken AU - Russell H. Swerdlow AU - John P. Thyfault TI - Mild cognitive impairment is associated with skeletal muscle mitochondrial deficits AID - 10.1101/2020.07.20.20158022 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.20.20158022 4099 - http://medrxiv.org/content/early/2020/07/25/2020.07.20.20158022.short 4100 - http://medrxiv.org/content/early/2020/07/25/2020.07.20.20158022.full AB - Alzheimer’s Disease (AD) is associated with insulin resistance and low cardiorespiratory fitness, suggestive of impaired skeletal muscle mitochondrial function. We examined if individuals with Mild Cognitive Impairment (MCI), the earliest phase of AD-related cognitive decline, exhibit reduced skeletal muscle mitochondrial function, and if AD medication impacted outcomes. We present data from 50 individuals, including cognitively healthy older adults (CH; n=24) 60+ years of age and clinically diagnosed MCI subjects (n=26). MCI subjects were sub-divided into two groups; no AD medication (MCI; n=11), or AD medication treated (MCI+med; n=15). A skeletal muscle biopsy (vastus lateralis) was obtained and mitochondrial respiratory kinetics was measured in permeabilized muscle fibers. MCI subjects exhibited lower lipid-stimulated skeletal muscle mitochondrial respiration (State 3, ADP-stimulated) than both CH individuals (p=0.043) and medication-treated MCI subjects (p=0.006). MCI also exhibited poorer mitochondrial coupling control compared to CH subjects (p=0.014), while MCI+med and CH subjects did not differ. Compared to CH individuals, skeletal muscle mitochondrial leak control ratio was lower for the MCI+med group (p=0.008) and trended lower for non-medicated MCI (p=0.06), which suggests greater mitochondrial uncoupling in MCI. Skeletal muscle mitochondrial respiration is impaired in untreated MCI but normalized in medication-treated MCI participants while mitochondrial leak control is impaired regardless of medication status. These results provide further evidence that systemic mitochondrial deficits occur in the very early stages of AD, and that mitochondrial function is partially influenced by AD medication. Further analysis for a role of muscle mitochondria in the progression of early AD is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo trial ID - observational study, not a clinical trial.Funding StatementThis project was supported by NIH R21AG056062-01 from the National Institute on Aging. Other support for the authors includes R00AG050490 and R01AG062548 (JKM) R01KD121497 and R01AR071263 (JPT); TL1TR002368 (CSM); K-INBRE P20 GM103418 (JKM, JPT); K99AG056600 (H.M.W), R21AG061548 (EVD), and P30AG035982. We would also like to thank Dr. Chris Perry for technical assistance, and thank our research participants for their invaluable contribution to this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Kansas Medical Center's Institutional Review Board (IRB # 140787). All participants in this study provided informed consent according to institutional guidelines and in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request following the publication of this manuscript.